- CNS stimulants
- Benzodiazepines
- Hypnotics
Obstructive Sleep Apnea Drugs Market size was valued at USD 9,153.7 million in 2022 and is poised to grow at a CAGR of 3.7% from 2023-2029. Sleep apnea is a sleeping disease caused by irregular breathing and oxygen deprivation of the brain. According to a study published in 2020 by the American Sleep Association, between 50 and 70 million people in the United States suffer from sleep disorders. According to research published by the American Sleep Association in 2020, an estimated 50 million to 70 million persons in the United States suffer from sleep disturbances. Furthermore, the Canadian Respiratory Journal reported in 2014 that around 5.4 million persons in Canada had been diagnosed with sleep apnea or were at risk of acquiring Obstructive sleep apnea. A surge in the prevalence of sleep apnea is majorly driving the growth of the sleep apnea treatment market.
Furthermore, the growing geriatric population, rising lifestyle changes, growing home care acceptance coupled with the awareness of sleepwear disorders, improving healthcare infrastructure, an introduction of new technologies, and innovative products are expected to fuel the growth of the sleep apnea treatment market. The massive pool of undiagnosed patients with sleep apnea holds tremendous potential for the sleep apnea devices market. The older population has a significant prevalence of sleep apnea, which is underdiagnosed due to lack of knowledge and the disease's non-specific presentation. Sleep disturbances are projected to become more common as the senior population grows as life expectancy increases. According to the WHO, the global population of persons aged 60 and more is predicted to reach 2.0 billion by 2050 in 2018. Because this population group is more susceptible to sleep apnea, an increase in the senior population is projected to enhance the use of these devices. Furthermore, because comorbidities linked with sleep apnea are high among the elderly, the prevalence of sleep apnea is rising in the geriatric population.
Study Period
2024-2030Base Year
2023CAGR
3.7%Largest Market
North AmericaFastest Growing Market
Europe
The enormous pool of undiagnosed sleep apnea patients, growing knowledge about the adverse effects of untreated sleep apnea, and an increasing number of players venturing into the sleep apnea industry are driving market expansion. With the ongoing awareness campaigns and efforts, it is envisaged that a new patient base will be diagnosed and treated for sleep apnea. However, the sleep apnea treatment market is projected to be hampered by tight regulatory procedures, pharmacological side effects, and intense market rivalry.
The prevalence rate of obstructive sleep apnea (OSA) is increasing rapidly across the globe which increases risk of road traffic, work-related accidents, cardiovascular diseases and strokes. As per the National Commission on Sleeping Disorders Research, globally about 38,000 deaths are accounting annually owing to the cardiovascular problems associated with sleep apnea. OSA is also correlated with heart failure which is 12-16% more prevalent in OSA patients. It has also been observed that approximately 60-70% of OSA patients are obese. Increasing prevalence of Obstructive Sleep Apnea is associated with number of cardiac and metabolic diseases. However, awareness, diagnosis, and treatment of Obstructive Sleep Apnea could offer significant savings to the patient
By Drugs
By Distribution Channel
By Geography
The obstructive sleep apnea drugs market size was valued at USD 9,153.7 million in 2022
Rising Prevalence of Sleep Apnea and Upsurge in Geriatric Population
Europe is the fastest-growing for obstructive sleep apnea drugs market
1. Executive Summary |
2. Global Obstructive Sleep Apnea Drugs Market Introduction |
2.1.Global Obstructive Sleep Apnea Drugs Market - Taxonomy |
2.2.Global Obstructive Sleep Apnea Drugs Market - Definitions |
2.2.1.Drugs |
2.2.2.Distribution Channel |
2.2.3.Region |
3. Global Obstructive Sleep Apnea Drugs Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Product Landscape |
3.6. New Product Launches |
3.7. Impact of COVID 19 on Market |
4. Global Obstructive Sleep Apnea Drugs Market Analysis, 2018 - 2022 and Forecast 2023 - 2029 |
4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5. Global Obstructive Sleep Apnea Drugs Market By Drugs, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
5.1. CNS stimulants |
5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Benzodiazepines |
5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Hypnotics |
5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
6. Global Obstructive Sleep Apnea Drugs Market By Distribution Channel, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
6.1. Hospital pharmacies |
6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Retail Pharmacies |
6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Online Pharmacies |
6.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
7. Global Obstructive Sleep Apnea Drugs Market By Region, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
7.1. North America |
7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Europe |
7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Asia Pacific (APAC) |
7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
7.4. Middle East and Africa (MEA) |
7.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.4.3. Market Opportunity Analysis |
7.5. Latin America |
7.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.5.3. Market Opportunity Analysis |
8. North America Obstructive Sleep Apnea Drugs Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
8.1. Drugs Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
8.1.1.CNS stimulants |
8.1.2.Benzodiazepines |
8.1.3.Hypnotics |
8.2. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
8.2.1.Hospital pharmacies |
8.2.2.Retail Pharmacies |
8.2.3.Online Pharmacies |
8.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
8.3.1.United States of America (USA) |
8.3.2.Canada |
9. Europe Obstructive Sleep Apnea Drugs Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
9.1. Drugs Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.1.1.CNS stimulants |
9.1.2.Benzodiazepines |
9.1.3.Hypnotics |
9.2. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.2.1.Hospital pharmacies |
9.2.2.Retail Pharmacies |
9.2.3.Online Pharmacies |
9.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.3.1.Germany |
9.3.2.France |
9.3.3.Italy |
9.3.4.United Kingdom (UK) |
9.3.5.Spain |
9.3.6.Rest of EU |
9.3.7. |
10. Asia Pacific (APAC) Obstructive Sleep Apnea Drugs Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
10.1. Drugs Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1.CNS stimulants |
10.1.2.Benzodiazepines |
10.1.3.Hypnotics |
10.2. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1.Hospital pharmacies |
10.2.2.Retail Pharmacies |
10.2.3.Online Pharmacies |
10.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1.China |
10.3.2.India |
10.3.3.Australia and New Zealand (ANZ) |
10.3.4.Japan |
10.3.5.Rest of APAC |
11. Middle East and Africa (MEA) Obstructive Sleep Apnea Drugs Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
11.1. Drugs Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1.CNS stimulants |
11.1.2.Benzodiazepines |
11.1.3.Hypnotics |
11.2. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1.Hospital pharmacies |
11.2.2.Retail Pharmacies |
11.2.3.Online Pharmacies |
11.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1.GCC Countries |
11.3.2.South Africa |
11.3.3.Rest of MEA |
12. Latin America Obstructive Sleep Apnea Drugs Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
12.1. Drugs Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1.CNS stimulants |
12.1.2.Benzodiazepines |
12.1.3.Hypnotics |
12.2. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1.Hospital pharmacies |
12.2.2.Retail Pharmacies |
12.2.3.Online Pharmacies |
12.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1.Brazil |
12.3.2.Mexico |
12.3.3.Rest of LA |
13. Competition Landscape |
13.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
13.2.1.Biogen, Inc (U.S). |
13.2.2.Pfizer, Inc. (U.s) |
13.2.3.Johnson & Johnson Services, Inc. (U.S) |
13.2.4.Otsuka America Pharmaceutical, Inc. (U.S) |
13.2.5.Eli Lilly & Company (U.S) |
13.2.6.Merck & Co., Inc. (U.S) |
13.2.7.AstraZeneca (UK) |
13.2.8.Novartis AG (Switzerland) |
14. Research Methodology |
15. Appendix and Abbreviations |